The Food and Drug Administration (FDA) have given approval to Johnson & Johnson's diabetes drug Invokana.
Invokana (canagliflozin) is the first in a new class of sodium-glucose co-transporter 2 (SGLT2) inhibitors to treat type 2 diabetes to be approved in the US. SGLT2 inhibitors block reabsorption of glucose by the kidney and thus increase glucose excretion from the body.
According to the Washington Post, analysts estimate that Invokana could become a blockbuster drug, generating more than $1 billion in sales.
"We continue to advance innovation with the approval of new drug classes that provide additional treatment options for chronic conditions that impact public health," said Dr. Mary Parks, director of the FDA's division of endocrinology products.
The approval follows last year's rejection by the FDA of AstraZeneca and Bristol-Myers Squibb's SGLT2 inhibitor Forxiga (dapagliflozin) on the basis of safety concerns, but was approved for sale in Europe.
Do you think that SGLT2 inhibitors will take off?
You can join our discussion on LinkedIn, or leave a comment below.